The Federal Trade Commission said pharmacy benefit managers created a "perverse drug rebate system" that artificially ...

MADRID — Day of the week, age, snacking, and being more engaged with smart insulin pens are important factors that affect ...

The global insulin pens market is experiencing rapid expansion, driven by the rising global prevalence of diabetes. According ...

Eli Lilly on Thursday said topline results from two late-stage studies showed that its weekly insulin injection had similar results to the widely used daily insulins. The drugmaker said topline ...

A pair of late-stage trials found that Eli Lilly & Co.’s experimental once-weekly insulin can lower blood sugar as effectively as widely used daily insulins, the drugmaker said Thursday ...

Eli Lilly (NYSE:LLY) on Thursday announced that its QWINT-1 and QWINT-3 Phase 3 clinical trials for once-weekly insulin efsitora alfa reached the primary endpoints against daily basal insulins ...

INDIANAPOLIS - Eli Lilly and Company (NYSE:LLY) revealed positive outcomes from two phase 3 clinical trials, QWINT-1 and QWINT-3, for its once-weekly insulin efsitora alfa (efsitora) in adults with ...

Thursday, Eli Lilly and Co (NYSE:LLY) released topline results from the QWINT-1 and QWINT-3 phase 3 trials evaluating once weekly insulin efsitora alfa (efsitora) in adults with type 2 diabetes.

INDIANAPOLIS - Eli Lilly and Company (NYSE:LLY) revealed positive outcomes from two phase 3 clinical trials, QWINT-1 and QWINT-3, for its once-weekly insulin efsitora alfa (efsitora) in adults ...

(RTTNews) - Eli Lilly and Company (LLY) Thursday announced positive topline results from the QWINT-1 and QWINT-3 phase 3 studies evaluating once weekly basal insulin efsitora alfa in adults with ...

Positive late-stage trial results come after Novo Nordisk's weekly insulin was rejected by FDA A pair of late-stage trials found that Eli Lilly & Co.'s experimental once-weekly insulin can lower ...